Rigontec is the leader in RIG-I targeting therapeutics. Utilizing our proprietary RIG-I agonist platform, we harness one of the most essential pathways in the innate immune system to pioneer a novel immuno-oncology treatment approach.
Rigontec’s proprietary agonists specifically activate RIG-I, inducing both immediate and long-term anti-tumor immunity and have proven substantial local and systemic tumor regression in several relevant in vivo models.
In addition to malignant diseases, our innovative bifunctional RNA molecules can be developed for the treatment of infectious and inflammatory diseases.
